BioCentury
ARTICLE | Company News

Bosley leaving Editas as CRISPR company moves toward clinic

January 22, 2019 5:56 PM UTC

Editas Medicine Inc. (NASDAQ:EDIT) said Katrine Bosley is stepping down as president and CEO, effective March 1. Cynthia Collins, a director since December, will be interim CEO while the gene editing company searches for a successor.

Spokesperson Cristi Barnett told BioCentury that Bosley's decision to leave Editas comes as the company moves into its next phase of growth. The gene editing company and partner Allergan plc (NYSE:AGN) are set to begin clinical trials next half of CRISPR therapeutic EDIT-101 to treat Leber congenital amaurosis type 10 (LCA10) (see "Editas to Enter Clinic with In Vivo CRISPR Therapy")...

BCIQ Company Profiles

Editas Medicine Inc.